Study of 89Zr-pembrolizumab PET/CT in patients with advanced-stage non–small cell lung cancer
ALN Niemeijer, DE Oprea-Lager… - Journal of Nuclear …, 2022 - Soc Nuclear Med
The tumor programmed death ligand 1 (PD-L1) proportion score is the current method for
selecting non–small cell lung cancer (NSCLC) patients for single-agent treatment with …
selecting non–small cell lung cancer (NSCLC) patients for single-agent treatment with …
PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non–Small Cell Lung Cancer
J Smit, FJ Borm, ALN Niemeijer… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Better biomarkers are needed to predict treatment outcome in non–small cell lung cancer
(NSCLC) patients treated with anti–programmed death-1/programmed death-ligand 1 (PD …
(NSCLC) patients treated with anti–programmed death-1/programmed death-ligand 1 (PD …
Early phase I study of a 99mTc-labeled anti–programmed death ligand-1 (PD-L1) single-domain antibody in SPECT/CT assessment of PD-L1 expression in non–small …
Y Xing, G Chand, C Liu, GJR Cook… - Journal of Nuclear …, 2019 - Soc Nuclear Med
Immunotherapy with checkpoint inhibitor programmed cell death 1 (PD-1)/programmed
death ligand-1 (PD-L1) antibodies demonstrates improvements in treatment of advanced …
death ligand-1 (PD-L1) antibodies demonstrates improvements in treatment of advanced …
[HTML][HTML] 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer
IC Kok, JS Hooiveld, PP van de Donk, D Giesen… - Annals of …, 2022 - Elsevier
Background Programmed cell death protein 1 (PD-1) antibody treatment is standard of care
for melanoma and non-small-cell lung cancer (NSCLC). Accurately predicting which patients …
for melanoma and non-small-cell lung cancer (NSCLC). Accurately predicting which patients …
Comparison of RECIST, iRECIST, and PERCIST for the evaluation of response to PD-1/PD-L1 blockade therapy in patients with non–small cell lung cancer
Purpose The aim of this study was to compare the Response Evaluation Criteria in Solid
Tumors (RECIST) 1.1, the immune RECIST (iRECIST) criteria, and the Positron Emission …
Tumors (RECIST) 1.1, the immune RECIST (iRECIST) criteria, and the Positron Emission …
[HTML][HTML] Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
O Yamaguchi, K Kaira, K Hashimoto, A Mouri… - Scientific reports, 2020 - nature.com
There is a lack of markers for predicting favorable outcomes after pembrolizumab therapy in
patients with non-small cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1) …
patients with non-small cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1) …
Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC
K Kaira, T Higuchi, I Naruse, Y Arisaka, A Tokue… - European journal of …, 2018 - Springer
Background Nivolumab, an anti-programmed death-1 (PD-1) antibody, is administered in
patients with previously treated non-small cell lung cancer. However, little is known about …
patients with previously treated non-small cell lung cancer. However, little is known about …
First-in-humans evaluation of a PD-L1–binding peptide PET radiotracer in non–small cell lung cancer patients
X Zhou, J Jiang, X Yang, T Liu, J Ding… - Journal of Nuclear …, 2022 - Soc Nuclear Med
68Ga-NOTA-WL12 is a peptide-based PET imaging agent. We conducted a first-in-human
study of 68Ga-NOTA-WL12 for PET to study the in vivo biodistribution, metabolism, radiation …
study of 68Ga-NOTA-WL12 for PET to study the in vivo biodistribution, metabolism, radiation …
Comparison between 18F-FDG PET–based and CT-based criteria in non–small cell lung cancer Patients treated with nivolumab
Because of the peculiar mechanism of action of immune checkpoint inhibitors (ICIs),
evaluation of the radiologic response to them in solid tumors presents many challenges. We …
evaluation of the radiologic response to them in solid tumors presents many challenges. We …
[HTML][HTML] 18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer
K Takada, G Toyokawa, Y Yoneshima, K Tanaka… - Scientific reports, 2019 - nature.com
To examine the association between 18F-fluorodeoxyglucose (18F-FDG) uptake in positron
emission tomography/computed tomography (PET/CT) and the response to anti …
emission tomography/computed tomography (PET/CT) and the response to anti …